司库奇尤单抗与阿达木单抗治疗银屑病关节炎合并中重度斑块状银屑病的疗效:EXCEED随机双盲头对头单药研究
EXCEED研究预设分析纳入211例银屑病关节炎合并中重度斑块状银屑病患者,随机接受司库奇尤单抗300mg或阿达木单抗40mg治疗。
要点
- 司库奇尤单抗在皮肤清除(PASI 100)方面优于阿达木单抗。
- ACR20应答两组无显著差异,关节症状改善相当。
核心结论
- 在银屑病关节炎合并中重度斑块状银屑病患者中,司库奇尤单抗在皮肤终点上持续优于阿达木单抗。
研究设计与样本
- EXCEED随机双盲头对头单药研究,共853例患者随机分配至司库奇尤单抗组(N=426)或阿达木单抗组(N=427)。
- 中重度银屑病定义为基线受累体表面积>10%或PASI≥10。
- 司库奇尤单抗300mg皮下注射于基线、第1-4周、之后每4周至第48周;阿达木单抗40mg皮下注射每2周至第50周。
- 缺失数据采用多重插补处理。
主要发现
- 司库奇尤单抗在所有皮肤终点上均显示持续高于阿达木单抗的应答。
临床怎么用
- 对于银屑病关节炎合并中重度斑块状银屑病患者,司库奇尤单抗可作为兼顾皮肤与关节的综合生物治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secukinumab [an interleukin (IL)-17A inhibitor] has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL-12/23 inhibitor) in patients with moderate-to-severe plaque psoriasis. OBJECTIVES: To report 52-week results from a prespecified analysis of patients with active psoriatic arthritis (PsA) having concomitant moderate-to-severe plaque psoriasis from the head-to-head EXCEED monotherapy study comparing secukinumab with adalimumab. METHODS: Patients were randomized to receive secukinumab 300 mg via subcutaneous injection at baseline, week 1-4, and then every 4 weeks until week 48 or adalimumab 40 mg via subcutaneous injection every 2 weeks from baseline until week 50. Assessments in patients with concomitant moderate-to-severe psoriasis, defined as having affected body surface area > 10% or Psoriasis Area and Severity Index (PASI) ≥ 10 at baseline, included musculoskeletal, skin and quality-of-life outcomes. Missing data were handled using multiple imputation. RESULTS: Of the 853 patients [secukinumab (N = 426), adalimumab (N = 427)], 211 (24·7%) had concomitant moderate-to-severe psoriasis [secukinumab (N = 110, 25·8%), adalimumab (N = 101, 23·7%)]. Up to week 50, 5·5% of patients discontinued secukinumab vs.17·8% in the adalimumab group. The proportion of patients who achieved American College of Rheumatology (ACR) 20 response was 76·4% with secukinumab vs. 68·3% with adalimumab (P = 0·175), PASI 100 response was 39·1% vs. 23·8% (P = 0·013), and simultaneous improvement in ACR 50 and PASI 100 response at week 52 was 28·2% vs. 17·7%, respectively (P = 0·06). Secukinumab demonstrated consistently higher responses vs. adalimumab across skin endpoints. CONCLUSIONS: This prespecified analysis in PsA patients with concomitant moderate-to-severe plaque psoriasis in the EXCEED study provides further evidence that IL-17 inhibitors offer a comprehensive biological treatment to manage the concomitant features of psoriasis and PsA.
引用
- Gottlieb AB, Merola JF, Reich K, et al. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. Br J Dermatol. 2021. PMID: 33913511. doi:10.1111/bjd.20413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。